Viridian Therapeutics Files 8-K on Financials
Ticker: VRDN · Form: 8-K · Filed: May 6, 2025 · CIK: 1590750
Sentiment: neutral
Topics: financial-condition, financial-statements, company-history
TL;DR
Viridian Therapeutics (VRDN) filed an 8-K on May 6th detailing financial results and exhibits.
AI Summary
Viridian Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The company, formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc., is incorporated in Delaware and headquartered in Waltham, MA.
Why It Matters
This filing provides an update on Viridian Therapeutics' financial performance and condition, which is crucial for investors to assess the company's stability and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any new material events or significant negative news.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- May 6, 2025 (date) — Date of earliest event reported
- Miragen Therapeutics, Inc. (company) — Former company name
- Signal Genetics, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Waltham, MA (location) — Business address
FAQ
What specific financial information is being reported in this 8-K?
The 8-K indicates it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on May 6, 2025.
What were Viridian Therapeutics' former company names?
Viridian Therapeutics was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
In which state is Viridian Therapeutics incorporated?
Viridian Therapeutics is incorporated in Delaware.
What is the business address of Viridian Therapeutics?
The business address is 221 Crescent Street, Suite 103A, Waltham, MA 02453.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 6, 2025 regarding Viridian Therapeutics, Inc.\DE (VRDN).